AI-Powered Medication Adherence App for First Episode Psychosis

Recruiting at 4 trial locations

Overseen By Cristina Gonzalez, MS

Age: < 65

Sex: Any

Trial Phase: Phase 4

Sponsor: Northwell Health

Must be taking: Antipsychotics

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

200 Participants Needed

Trial Summary

What is the purpose of this trial?

The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis.

Eligibility Criteria

This trial is for individuals enrolled in a Coordinated Specialty Care (CSC) program who have been prescribed an oral antipsychotic medication to manage conditions like psychosis or first episode psychosis. There are no specific exclusion criteria, so it's open to anyone meeting the inclusion requirements.

Inclusion Criteria

I am taking an oral antipsychotic medication.

Enrolled in a CSC program

Exclusion Criteria

Not applicable.

Treatment Details

Interventions

• Smartphone App
• Usual Care

Trial Overview The study is testing an artificial intelligence-powered smartphone app designed to help patients with their adherence to taking oral antipsychotic medications regularly as compared to the usual care without such technological support.

Participant Groups

Group I: Smartphone App Experimental Treatment 1 Intervention

artificial intelligence (AI) smartphone app to provide support for medication adherence

Group II: Usual Care Active Control 1 Intervention

Usual care provided at CSC clinic

Who Is Running the Clinical Trial?

Northwell Health

Lead Sponsor

Trials

481

Recruited

470,000+

National Institute of Mental Health (NIMH)

Collaborator

Trials

3,007

Recruited

2,852,000+